ACT gains exclusive license for blood-related stem cell tech

Thu, 07/21/2011 - 10:42am
Mass High Tech: The Journal of New England Technology

Advanced Cell Technology Inc. is gaining an exclusive license to hemangioblast cell technology, for potential use in vascular repair, from a joint venture the Marlborough company formed with South Korea-based CHA Bio & Diostech Co Ltd. The venture, Stem Cell & Regenerative Medicine International (SCRMI), is shifting from a research entity to a licensing body, as both ACT and CHA Bio pursue hemagioblast cell developments.

As part of the deal, ACT will also add 10 SCRMI employees who were conducting research on differentiating human embryonic stem cells and induced pluripotent stem cells into hemangioblasts, which ACT chief scientific officer Robert Lanza noted in a press release could help carry red blood cells or platelets.




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.